文献速递泌尿生殖腹部MR

MRI透明细胞可能性评分与小型实性肾肿块主动监测生长动力学的关联

Association of Clear Cell Likelihood Score on MRI and Growth Kinetics of Small Solid Renal Masses on Active Surveillance.
PubMed 文献 · AJR Am J Roentgenol · 2021-07-21

这项回顾性研究纳入386个小肾肿块(cT1a,≤4 cm),评估MRI透明细胞可能性评分(ccLS)与生长速率及进展的关系。结果显示ccLS与肿瘤生长速率相关,ccLS 4-5组年增长率高于ccLS 1-2组,但疾病进展与ccLS组无显著关联。提示低ccLS者可考虑主动监测,高ccLS者可能需早期干预。

要点

  • ccLS越高,小肾肿块生长越快,ccLS 4-5组年增长9%,ccLS 1-2组5%。
  • ccLS与疾病进展无显著关联,进展组间差异无统计学意义。
  • 低ccLS小肾肿块可考虑主动监测,高ccLS者可考虑早期干预。

局限性

  • 回顾性研究设计。
  • 单中心或附属医院系统。
  • 中位随访时间较短(1.2年)。
  • ccLS从临床报告提取,可能存在评分者间差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. The lack of validated imaging markers to characterize biologic aggressiveness of small renal masses (SRMs)-defined as those categorized as cT1a and 4 cm and smaller-hinders medical decision-making among available initial management strategies. OBJECTIVE. The purpose of this article was to explore the association of the clear cell likelihood score (ccLS) on MRI with growth rates and progression of SRMs. METHODS. This retrospective study included consecutive SRMs assigned a ccLS on clinical MRI examinations performed between June 2016 and November 2019 at an academic tertiary-care medical center or its affiliated safety net hospital system. The ccLS reports the likelihood that the SRM represents clear cell renal cell carcinoma (ccRCC) from 1 (very unlikely) to 5 (very likely). The ccLS was extracted from clinical reports. Tumor size measurements were extracted from available prior and follow-up cross-sectional imaging examinations, through June 2020. Serial tumor size measurements were fit to linear and exponential growth curves. Estimated growth rates were grouped by the assigned ccLS. Tumor progression was defined by development of large size (> 4 cm in at least two consecutive measurements) and/or rapid growth (doubling of volume within 1 year). Differences among ccLS groups were evaluated using Kruskal-Wallis tests. Correlations between ccLS and growth rate were evaluated by Spearman correlation (ρ). RESULTS. Growth rates of 386 SRMs (100 ccLS 1-2, 75 ccLS 3, and 211 ccLS 4-5) from 339 patients (median age, 65 years; 198 men, 141 women) were analyzed. Median follow-up was 1.2 years. The ccLS was correlated with growth rates by size (ρ = 0.19; p < .001; ccLS 4-5, 9%/year; ccLS 1-2, 5%/year; p < .001) and by volume (ρ = 0.14; p = .006; ccLS 4-5, 29%/year; ccLS 1-2, 16%/year; p < .001). Disease progression (observed in 49 SRMs) was not significantly associated with ccLS group (p = .61). Two patients (0.6%) developed metastases during active surveillance: one ccLS 1 was a type 2 papillary renal cell carcinoma and one ccLS 4 was ccRCC. CONCLUSION. Growth is associated with ccLS in SRMs, with higher ccLS correlating with faster growth. CLINICAL IMPACT. SRMs with lower ccLS may be considered for active surveillance, whereas SRMs with higher ccLS may warrant earlier intervention. The noninvasive ccLS derived from MRI correlates with growth rate of SRMs and may help guide personalized management.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Rasmussen RG, Xi Y, Sibley RC, et al. Association of Clear Cell Likelihood Score on MRI and Growth Kinetics of Small Solid Renal Masses on Active Surveillance. AJR Am J Roentgenol. 2021. PMID: 34286596. doi:10.2214/AJR.21.25979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。